Predicting responses to omalizumab in antihistamine-refractory chronic urticaria: A real-world longitudinal study.

J Allergy Clin Immunol Glob · 2024 · PMC10992700 · PMID 38577481

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

17 , 29 , 30 In our study, we observed a notable trend of higher PLRs being associated with a higher likelihood of being a late responder to omalizumab treatment.

also in 2,105 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.